AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
Go back to AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia| AbbVie (NYSE: ABBV) | Delayed: 230.01 +13.52 (6.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $216.49 | 52 Week High | $68.12 | |||
| Open | $221.94 | 52 Week Low | $50.71 | |||
| Day High | $232.32 | P/E | 49.89 | |||
| Day Low | $221.94 | EPS | $4.61 | |||
| Volume | 9,702,418 | |||||
